[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644539":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":72,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Icahn School of Medicine at Mount Sinai","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"scheduled term c-section",null,"Patients scheduled for term cesarean deliveries and who are screened eligible and consented will be administered a continuous glucose monitor prior to their c-section, and they will wear the device through their stay in the hospital.",[13],"Device: Continuous Glucose Monitor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Continuous Glucose Monitor","Continuous glucose monitor during perioperative Cesarean delivery",[9],[21],{"name":22,"affiliation":23,"role":24},"Angela Bianco, MD","Faculty","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Nicola F Tavella, MPH","CONTACT","(212) 241-3888","nicola.tavella@mssm.edu",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Kavya Shivashankar, MD","(212) 241-5681","kavya.shivashankar@mssm.edu",[36],{"facility":5,"status":10,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"New York","10029","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-74.00597,40.71427,{"lat":45,"lon":44},[48,50],{"name":27,"role":28,"phone":49,"phoneExt":10,"email":30},"2122413888",{"name":51,"role":24,"phone":10,"phoneExt":10,"email":10},"Angela Bianco",{"type":24,"investigatorFullName":51,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Director, Division of Maternal-Fetal Medicine","100644539","perioperative-use-of-continuous-glucose-monitoring-for-scheduled-cesarean-deliveries-peruse-100644539",false,"NCT07671599","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)","Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study","PERUSE","Inclusion Criteria:\n\n* singleton pregnancy\n* no prior diagnosis of diabetes (gestational included)\n* scheduled term cesarean delivery in Mount Sinai Health System\n* aged 18-50 years\n\nExclusion Criteria:\n\n* preexisting diabetes mellitus\n* diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening\n* known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.)\n* use of antenatal steroids within the two weeks prior to delivery","ALL","18 Years","50 Years",{"count":66,"type":67},150,"ESTIMATED","OBSERVATIONAL","This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.",[71],"Dysglycemia","NOT_YET_RECRUITING","2026-06-22",{"date":75,"type":76},"2026-06-26","ACTUAL",{"date":78,"type":67},"2026-09",{"date":80,"type":67},"2028-05",{"name":5,"class":6},1]